Teicoplanin as an effective alternative to vancomycin for treatment of MRSA infection in Chinese population: a meta-analysis of randomized controlled trials

Peng, Yang, Ye, Xiaohua, Li, Ying, Bu, Tao, Chen, Xiaofeng, Bi, Jiaqi, Zhou, Junli and Yao, Zhenjiang (2013) Teicoplanin as an effective alternative to vancomycin for treatment of MRSA infection in Chinese population: a meta-analysis of randomized controlled trials. PLoS One, 8 11: 1-8. doi:10.1371/journal.pone.0079782


Author Peng, Yang
Ye, Xiaohua
Li, Ying
Bu, Tao
Chen, Xiaofeng
Bi, Jiaqi
Zhou, Junli
Yao, Zhenjiang
Title Teicoplanin as an effective alternative to vancomycin for treatment of MRSA infection in Chinese population: a meta-analysis of randomized controlled trials
Journal name PLoS One   Check publisher's open access policy
ISSN 1932-6203
Publication date 2013-11-18
Sub-type Article (original research)
DOI 10.1371/journal.pone.0079782
Open Access Status DOI
Volume 8
Issue 11
Start page 1
End page 8
Total pages 8
Place of publication San Francisco, CA United States
Publisher Public Library of Science
Language eng
Formatted abstract
Objective

To evaluate whether teicoplanin could be an alternative to vancomycin for treatment of MRSA infection in Chinese population using a meta-analysis in randomized controlled trials.

Methods

The following databases were searched: Chinese Biomedical Literature database (CBM), Chinese Journal Full-text database (CNKI), Wanfang database, Medline database, Ovid database and Cochrane Library. Articles published from 2002 to 2013 that studied teicoplanin in comparison to vancomycin in the treatment of MRSA infected patients were collected. Overall effects, publishing bias analysis and sensitivity analysis on clinical cure rate, microbiologic eradication rate and adverse events rate were performed by using Review Manager 5.2 and Stata 11.0 softwares.

Results

Twelve articles met entry criteria. There was no statistically significant difference between the two groups regarding the clinical cure rate (risk ratio [RR], teicoplanin vs vancomycin, 0.94; 95% CI, 0.74∼1.19; P = 0.60), microbiological cure rate (risk ratio [RR], teicoplanin vs vancomycin, 0.99; 95% CI, 0.91∼1.07; P = 0.74) and adverse event rate (risk ratio [RR], teicoplanin vs vancomycin, 0.86; 95% CI, 0.40∼1.84; P = 0.70).

Conclusions

The meta-analysis results indicate that the two therapies are similar in both efficacy and safety, thus teicoplanin can act as an effective alternative to vancomycin for treating patients infected by MRSA.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 1 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 28 Apr 2016, 18:21:02 EST by Yang Peng on behalf of Medicine - Royal Brisbane and Women's Hospital